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and physical properties in cell response, 
tissue maintenance, regeneration and dis-
ease. Synthetic cell instructive materials 
allow independent control of biochemical 
and biophysical properties by combining 
(i) particular polymers, (ii) crosslinking 
mechanisms, (iii) degradability, (iv) cell 
adhesion molecules and (v) biochemical 
factors – in solution, as well as surface-
bound, either covalently tethered or 
sequestered through physico-chemical 
affinity with the matrix. Such multi-par-
ametric hydrogels have enabled ground-
breaking studies on how cells sense 
biochemical and biophysical stimuli, 
as well as synergistic effects between 
them. Lutolf, Clevers and colleagues have 
recently shown the great potential of fully-
defined, degradable poly(ehtylene glycol)-
based (PEG) hydrogels, enriched with 
fibronectin or laminin-111, as designer 3D 
microenvironment for the organoid com-
munity,[1] so far predominantly limited to 
Matrigel, albeit lack of control in composi-
tion, chemical and physical properties. In this progress report 
we summarize key works in the fields of GF signalling and 
mechanotransduction, and discuss synergistic effects between 
the two. Such understanding of cell-matrix interaction is central 
in the development of new biomedical devices for regenerative 
medicine. For a more comprehensive understanding of the role 
of neighbouring cells we refer to several other reviews.[2–5]
2. Material-Based Systems for Efficient 
Presentation of Growth Factors
2.1. Solid-Phase Presentation of Growth Factors
Growth factors (GF) are key biochemical stimuli that promote 
cell proliferation, migration and differentiation. GFs play a 
fundamental role in embryonic development and are also 
involved in a range of physiological and pathological processes, 
including tissue repair and maintenance.[6,7]
Both in vitro and in vivo it is still common to use GFs in solu-
tion, either directly added to the culture media or released from 
a biomaterial carrier.[8–11] This is rather inefficient and unsafe 
as it uses high concentrations of GFs. Conceptually, it ignores 
that GFs in the body are bound to the ECM, as both proteins 
and glycosaminoglycans (GAGs) have GFs binding sites.[12] It 
was soon realized that the administration of GFs bound to a 
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1. Introduction
The local tissue microenvironment or cell niche includes the 
extracellular matrix (ECM), biochemical factors (soluble or 
surface-bound) and neighbouring cells; the interaction between 
the three of them regulates cell function (Figure 1). Biochem-
ical factors have been extensively investigated by the stem cell 
and organoid communities due to their direct impact in trig-
gering biochemical pathways. In the last decade, great progress 
has been made in understanding the role of ECM chemical 
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surface, i.e. solid-phase presentation of GFs, resulted in higher 
efficiency compared to soluble release, improved biological 
functions and reduced concentration and dose.[13–15]Figure 2 
shows a sketch of classical (soluble) vs. surface-bound presenta-
tion of GFs.
Insulin was one of the first GFs immobilized on mate-
rial surfaces but with no obvious correlation with biological 
activity.[17] It was more than 20 years later when it was shown 
that low doses of insulin immobilized on polymers had higher 
mitogenic effect than free insulin.[18] Simultaneously, it was 
shown that epidermal GF (EGF) could be tethered to surfaces 
retaining its biological activity and with control of temporal and 
spatial availability.[19] However, besides these early successes it 
took another decade to investigate systematically the effect of 
GFs bound to surfaces.
Most relevant studies involved different GFs and strategies 
to present them from surfaces: Insulin-like GF-1 (IGF-1) teth-
ered on self-assembled peptides increased the expression of 
troponin-I in cardiomyocytes in vitro, and improved systolic 
function after infarction in vivo.[20] Vascular endothelial GF 
(VEGF) retained within collagen gels (through an ECM binding 
domain) prolonged activation of its receptor VEGFR2 and acti-
vated β1 integrin, which had not been observed with soluble 
VEGF.[21] One of the first studies using stem cells revealed that 
surface-bound EGF promoted both cell spreading and survival 
more strongly than saturating concentrations of soluble EGF.[22]
Cavalcanti-Adam et al. investigated the influence of the dis-
tribution of bone morphogenetic protein (BMP)-2 using block 
copolymer micellar nanolithography to fabricate substrates 
with precisely spaced and tunable gold nanoparticle arrays car-
rying single BMP-2 molecules. They showed that surface pres-
entation of BMP-2 promoted enhanced Smad signaling com-
pared to soluble administration of the GF.[23] Segura et al. used 
nanoparticles functionalized with VEGF into a fibrin matrix to 
show that once GFs are bound to a surface, there are still some 
degrees of freedom in GF presentation (e.g. the density and 
organisation on the surface) that can influence GF activity.[24]
2.2. Affinity-Based Systems for the Presentation  
of Growth Factors
Some of the pioneering studies on ‘solid-phase’ presentation 
of GFs used covalent tethering of GFs to surfaces.[19,25] How-
ever, exploiting the natural affinity of ECM components (GAGs 
and structural proteins) towards GFs has resulted in the devel-
opment of GF sequestering biomaterials, which incorporate 
defined sequences of amino acids to promote GF binding. This 
approach has been called in some papers affinity-based sys-
tems.[26–28] In addition, these systems allow presentation of GFs 
that can be further internalized following receptor binding.[29,30] 
Seeking to engineer localized GFs reservoirs, layer-by-layer (LbL) 
assemblies of polyelectrolytes, which alternate positive and neg-
ative charged macromolecules have been used.[31] Picart et al. 
incorporated BMP-2 into poly(l-lysine)/hyaluronan (PLL/HA) 
LbLs and showed that the amount of BMP-2 loaded in the 
system could be controlled by varying the number of layers 
assembled.[32] BMP-2 was afterwards slowly released from the 
system, still bioactive, to drive osteogenic cell differentiation.[32]
2.3. Systems that Promote Growth Factor  
Receptor – Integrin Crosstalk
The solid-phase presentation of GFs allows better control of 
their spatial distribution to target GF receptors. Early works 
revealed the bidirectional cross-modulation of integrins and GF 
receptors, e.g. β1 integrin and epithelial growth factor receptor 
in epithelial cells.[33] Then, and more specifically, the simulta-
neous excitation of integrin and GF receptors was described 
in biology to promote synergistic GF signalling.[34] Here we 
describe materials engineered to promote GF receptor – inte-
grin crosstalk (Figure 3a) seeking to achieve high efficiency 
with low doses of GFs.
Fibronectin and its fragments have been used to engi-
neer synergistic GF microenvironments. Fibronectin con-
tains three kinds of domains which mediate interactions with 
other fibronectin molecules, other ECM molecules and cells 
(Figure 3b).[35] Sobel et al. identified the heparin II binding 
region of fibronectin (FNIII12-14) as a VEGF binding site.[36] 
They reported that fibronectin fragments including FNIII9-10 
(integrin binding region) and FNIII12-14 promoted enhanced 
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endothelial cell migration, proliferation and signalling.[36] Mar-
tino and Hubbell generalized this result to show that FNIII12-14 
not only bound VEGF but was actually a highly promiscuous 
region with affinity towards GFs from different families.[37]
Based on this ability of fibronectin to bind GFs, mate-
rial systems that presented GFs by promoting the crosstalk 
between integrins and GF receptors have been engineered.[16] 
For example, Martino and colleagues used a fibrin matrix 
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Figure 1. Cell microenvironment engineering targets soluble and surface-bound biochemical factors, chemical and physical properties of the extracel-
lular matrix and the interaction with neighbouring cells.
Figure 2. Solid-phase vs. soluble presentation of GFs. GFs bound to material systems are spatially confined and their diffusion is limited. Even if 
the overall concentration of GFs is low, these are presented in high local concentrations and have the potential to crosstalk with adhesion receptors. 
Reproduced with permission.[16] Copyright 2016, Royal Society of Chemistry.
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functionalized with two recombinant fragments of fibronectin 
joined together, FNIII9-10, to promote integrin binding and cell 
adhesion,[35] and FNIII12-14, to bind GFs.[37] They showed that 
the system enhanced the formation of tube-like structures in 
endothelial cells (with VEGF-A), sprouting of smooth muscle 
cells (with platelet-derived growth factor (PDGF)-BB) and dif-
ferentiation of mesenchymal stem cells (MSC) (with BMP-2).[38] 
In addition, the system promoted tissue repair in vivo: wound 
healing in a diabetic mice model (with VEGF-A165 and PDGF-
BB) and bone regeneration in a critical size skull defect (with 
BMP-2 and PDGF-BB) (Figure 3c).[38] Remarkably, this was done 
using low doses of GFs (<150 ng) which is relevant for a safe use 
of GFs in clinical applications. This work represented a major 
landmark in GF presentation and put synergistic integrin-GF 
signalling in the map as a way to use GFs efficiently and safely.
Similarly, in the context of bone repair, placenta growth 
factor (PlGF)-2123-144 fused to BMP-2 and PDGF-BB led to full 
regeneration in a critical-size skull defect using low concen-
trations of GFs (≈200 ng).[40] This study shows that the sole 
delivery of GFs without a biomaterial carrier might work effec-
tively by engineering GFs to bind to the ECM and, paradoxi-
cally, reveals the importance of GF presentation to maximise 
efficiency, even if in this case GFs were delivered topically and 
in solution, without biomaterials carriers.[40]
Adv. Healthcare Mater. 2017, 6, 1700052
Figure 3. Synergistic growth factor microenvironments based on integrin-GF receptor synergistic signalling. a) Simultaneous targeting of integrins 
and GF receptors leads to synergistic signalling which maximizes the effect of the GF. b) Fibronectin contains different kinds of domains, in particular 
FNIII9-10 promotes integrin binding whereas FNIII12-14 is a promiscuous GF binding region. Fibronectin is organized into nanonetworks on poly(ethyl 
acrylate) (PEA) surfaces with both domains available for interaction. c) The incorporation of a recombinant fragment of fibronectin than encompasses 
FNIII9-10/12-14 into a fibrin matrix promotes bone regeneration in vivo with low doses of GFs (≈150 ng). d) The addition of BMP-2 to fibronectin 
nanonetworks on PEA surfaces promotes co-localization of integrin β1 (green) and BMPRI (red). a) Reproduced with permission.[16] Copyright 2016, 
Royal Society of Chemistry. b,d) Reproduced with permission.[39] Copyright 2016, American Association for the Advancement of Science. c) Reproduced 
with permission.[38] Copyright 2011, American Association for the Advancement of Science.
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A different way to exploit the ability of fibronectin to bind 
GFs is by inducing the assembly of fibrillar structures, reca-
pitulating the physiological process of cell-mediated fibronectin 
fibrillogenesis, to allow exposure of domains otherwise una-
vailable in the globular conformation of the protein.[41–44] We 
noted that FNIII12-14 (GF binding region) is located next to the 
integrin binding region (FNIII9-10) with potential for syner-
gistic integrin/GF signaling. However, for this to be exploited, 
fibronectin must be open, unfolded, to have the relevant 
regions available for interaction (Figure 3b).[39]
We showed that some polymers, such as poly(alkyl 
acrylates), with length of the side chain above two (e.g. ethyl – 
PEA, butyl – PBA, hexyl – PHA) promoted fibronectin 
assembly into nanonetworks (Figure 3b).[45–47] This assembled 
fibronectin structure has the ability to present GFs in synergy 
with α5β1 integrins, i.e., the molecule is open and FNIII9-10 
and III12-14 regions are simultaneously available for interac-
tion. Indeed, using atomic force microscopy we showed that 
BMP-2 binds fibronectin nanonetworks previously assembled 
on PEA and then promotes co-localization of integrins and 
GF receptors resulting in enhanced canonical Smad signaling 
(Figure 3c).[39] This system used very low doses of BMP-2 
(25 ng ml−1) to promote MSC differentiation in vitro, as well 
as bone regeneration in a critical size defect in the mouse 
radius.[39] The assembly of fibronectin on PEA has been also 
effective in promoting integrin – VEGF signalling to enhance 
vascularisation.[48] One of the main advantages of using 
acrylates to promote high efficiency presentation of GFs is that 
the material can be applied through several technologies as 
coatings on biomedical devices, including scaffolds of complex 
anatomical 3D shapes.[49]
3. Physics of the Microenvironment and 
Mechanotransduction
The concept of “dynamic reciprocity” was postulated by Bissell 
and colleagues in 1981, whereby the cell nucleus and cytoskel-
eton, on the one hand, and the ECM, on the other, influence 
each other through physical and chemical interactions.[50] One 
decade later, Ingber and colleagues showed that cells can sense 
physical signals of the microenvironment using integrins, and 
then transmit this information throughout the cytoskeleton up 
to the nuclear structure, and thereby influence cell response.[51,52] 
He proposed a tensegrity-based transduction system and opened 
a new field of research, mechanotransduction.[53,54] Since then 
multiple features of the physics of the ECM been investigated.
3.1. Stiffness
The effect of substrate stiffness on cell migration and focal 
adhesions (FA) was first described two decades ago by Pelham 
and Wang.[55] Epithelial and fibroblastic cells exhibited 
reduced spreading, irregular-shaped and highly dynamic FAs, 
increased motility and lamellipodial activity on soft (5 kPa) 
compared to stiffer (70 kPa) collagen-coated polyacrylamide 
substrates. A vast number of publications followed this study, 
illustrating the relevance of the matrix mechanical properties 
on cell response.[56–60] A hallmark study by Engler and col-
leagues showed that matrix stiffness directs MSC fate, with soft 
(0.1–1 kPa), middle (8–17 kPa) or stiff (25–40 kPa) collagen-
coated polyacrylamide substrates favouring neurogenic, myo-
genic or osteogenic differentiation, respectively (Figure 4a).[61] 
Adv. Healthcare Mater. 2017, 6, 1700052
Figure 4. a) Hydrogel stiffness directs MSC fate on collagen-coated polyacrylamide 2D substrates and in (b) RGD-modified, non-degradable, ionically 
crosslinked alginate 3D matrices. Scale bars: (a) 20 µm, (b-i) 100 µm, (b-ii) 10 µm. a) Reproduced with permission.[61] Copyright 2006, Elsevier. 
b) Reproduced with permission.[62] Copyright 2010, Macmillan Publishers Limited.
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This work was extended to a three dimensional (3D) matrix by 
Huebsch and colleagues, who showed that MSCs differentiated 
towards adipogenic or osteogenic lineages at soft (2.5–5 kPa) or 
stiffer (11–30 kPa), RGD-modified, non-degradable, ionically 
crosslinked alginate hydrogels (Figure 4b).[62] Cell fate was not 
associated with differences in cell morphology, which remained 
unchanged, but rather with integrin clustering, which was 
maximized in stiffer hydrogels (Figure 4b). In a following 
study, void-forming, ionically crosslinked alginate hydrogels, 
consisting of (i) a bulk phase containing ex vivo encapsulated 
MSCs and stiffness optimized for osteogenic differentiation, 
and (ii) a sacrificial phase with degradable porogens, proved 
successful in the regeneration of 8 mm skull defects in nude 
rats.[63]
Some controversy arose with the work by Trappmann and 
colleagues, who showed that differences in collagen fibre 
tethering, caused by variations in pore size of polyacrylamide 
hydrogels with varying stiffness, altered local stiffness and 
influenced MSC fate.[64] Furthermore, collagen fibre tethering 
precisely altered by changing the spacing of gold nanoparticles 
also had an impact on cell differentiation. A follow up study 
by Engler and colleagues refuted in part these findings by fab-
ricating polyacrylamide substrates with an equivalent stiffness 
but changes in pore size and showing that stiffness, and not 
pore size or protein tethering, was more predictive of cell fate 
on 2D substrates.[65] This discussion, however, highlighted the 
concept that biological microenvironments are indeed fibrillar 
and that cell-matrix interactions differ substantially if the matrix 
is a nanoporous hydrogel, perceived as a continuum at the cell 
scale, or an engineered fibrillar microenvironment, with fibres 
of different local stiffness.[66]
3.2. Geometry
Contemporary to the work by Pelham and Wang, Chen and col-
leagues pioneered the idea that local geometry is a fundamental 
mechanism that regulates cell response. They controlled 
endothelial cell proliferation and apoptosis by simply allowing 
or restricting cell spreading (black), while maintaining the con-
tact area (grey) constant (Figure 5a).[67] In a following study, they 
developed a bed of microneedles to manipulate and measure cell 
traction forces as a function of the size of adhesion sites and cell 
spreading (Figure 5b).[68] It was shown that geometry-induced 
cytoskeletal tension and RhoA signalling could direct MSC 
fate, with osteogenic (adipogenic) differentiation associated 
Adv. Healthcare Mater. 2017, 6, 1700052
Figure 5. a) Cell spreading can dictate proliferation or apoptosis. b) Cell traction forces can be manipulated as a function of the size of the adhesion 
sites and cell spreading. (c The geometry of a collective of cells can regulate patterns of cell growth, favoured in regions of high traction stress. 
(d)Cells on a surface can sense and react to radii of curvature much larger than a single cell, with local tissue growth proportional to the local (concave) 
curvature. Scale bars: (b) 10 µm, (c) 100 µm. (a) eproduced with permission.[67] Copyright 1997, American Association for the Advancement of Sci-
ence. b) Reproduced with permission.[68] Copyright 2003, National Academy of Sciences. c) Reproduced with permission.[72] Copyright 2005, National 
Academy of Sciences. d) Reproduced with permission.[74] Copyright 2008, The Royal Society.
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to spread, flat morphology (unspread, round).[69] Kilian and 
colleagues demonstrated that single cells cultured on islands 
with rectangular or pentagonal symmetry, with varying subcel-
lular curvature but with an equivalent area, exhibited different 
osteogenesis or adipogenesis, with increased acto-myosin con-
tractility favouring the former.[70] These findings were extended 
to collective cell behaviour by culturing multicellular islands 
with different shapes.[71] The spatial gradients of traction forces 
mirrored MSC differentiation, with osteogenic (adipogenic) dif-
ferentiation at highly stressed edges (centre of island). Multi-
cellular geometry can also feedback to regulate patterns of cell 
growth, with regions of high traction stress favouring growth 
and branching morphogenesis (Figure 5c).[72,73] Cells on a sur-
face can sense and react to radii of curvature much larger than 
a single cell and regions with high local concave (convex) curva-
ture favour (inhibit) tissue growth (Figure 5d).[74,75]
On the other end of the size scale, surface nano- and micro-
topography influence size and shape of cell-matrix adhesion 
points and thus also play an important role in cell mecha-
notransduction, as well as in stem cell self-renewal and multi-
potency.[76–82] There are excellent reviews on the effect of nano-
topography on (stem) cells.[81,83]
3.3. Ligand Spacing
Cells sense and react to their surrounding environment 
through focal adhesions.[84] Spatz and colleagues pioneered the 
idea that spacing of adhesion peptides affects cell attachment, 
spreading and organisation of focal adhesions, and proposed 
58–73 nm as a universal length scale for integrin clustering and 
activation of cells cultured on 2D flat surfaces.[85] In a following 
study they showed that the formation of mature, stable focal 
adhesions and persistent cell spreading, but not cell adhe-
sion, was sensitive to ligand density.[86] With 108 nm spacing, 
cells exhibited a rapid turnover in focal adhesion formation, 
delayed spreading and repeated protrusion-retraction cycles 
compared to cells plated on 58 nm-spaced pattern. For ligand 
spacing >70 nm, the local order or disorder had an impact on 
cell adhesion, with increased (reduced) adhesion for disordered 
(ordered) ligands.[87]
3.4. Time-Dependent Biomaterial Physical Properties
The cell microenvironment is dynamic and undergoes remod-
elling with time. This is evident in physiological processes such 
as differentiation, morphogenesis, or maintenance of homeo-
stasis, as well as in progression of disease.[88] In the last years, 
dynamic biomaterial properties such time-dependent matrix 
stiffening, degradability, viscoelasticity and surface mobility 
are beginning to attract attention in the field of regenerative 
medicine.[89–92]
3.4.1. Time-Dependent Matrix Stiffening
Young and Engler presented one of the first studies describing 
hydrogel time-dependent stiffening to mimic developing 
myocardium.[93] Thiolated hyaluronic acid (HA) hydrogels 
were designed to stiffen from 1.9 ± 0.1 to 8.2 ± 1.1 kPa, imi-
tating the 9-fold increase in elastic modulus measured in 
developing embryonic chicken heart. A three-fold increase in 
mature cardiac specific markers and formation of up to 60% 
more maturing muscle fibres was observed on dynamic HA 
substrates compared to static polyacrylamide hydrogels. Guven-
diren and Burdick showed that the kinetics of light-mediated 
stiffening (≈3–30 kPa) of HA substrates modulated MSC differ-
entiation.[94] MSCs differentiated into osteoblasts (adipocytes) 
when stiffening took place within hours (within days-to-weeks) 
time, maximizing (minimizing) the time cells were on stiff sub-
strates. Stiffening HA substrates were used to mimic fibrosis 
and consequent myofibroblast activation in hepatic stellate 
cells.[95] Anseth and colleagues extended this work to cell-
laden 3D hydrogels using PEG-based hydrogels to investigate 
microenvironmental stiffening on valvular interstitial cell (VIC) 
activation.[96] VIC embedded in soft gels (0.24 kPa) exhibited a 
myofibroblast phenotype, while upon stiffening (to 1.2 or 13 kPa) 
via a photoinitiated thiol-ene polymerization, they reverted to a 
quiescent, fibroblast phenotype, irrespective of cell morphology. 
This was in contrast to previous 2D studies, where light-medi-
ated hydrogel softening (32 to 7 kPa) induced VIC deactivation, 
highlighting the importance of matrix dimensionality.[97,98]
3.4.2. Degradability
Biomaterials for tissue regeneration should degrade at a rate 
matching that of the new tissue growth.[99] Lutolf and col-
leagues pioneered matrix metalloproteinase (MMP)-sensitive 
hydrogels using PEG-based system.[100] They used a rat skull 
defect to show that bone regeneration, induced by BMP-2, was 
dependent on the sensitivity to MMP degradation. Khetan et 
al. highlighted the fact that cell response to matrix physical 
properties is highly dependent on the crosslinking method 
and degradation properties.[101] In contrast to previous studies 
showing stiffness-mediated MSC differentiation in non-degra-
dable, ionically crosslinked alginate hydrogels,[62] Khetan and 
colleagues reported that covalently crosslinked HA hydrogels, 
with equivalent stiffness (≈4 kPa) and enzymatic degradation 
(non-degradable), permitted (restricted) cell spreading, high 
(low) traction forces and favoured osteogenic (adipogenic) dif-
ferentiation (Figure 6a). A very recent study by Gjorevski et al. 
describes the use of fully-defined, degradable PEG-based gels, 
enriched with fibronectin or laminin-111, for intestinal stem 
cell (ISC) and organoid culture.[1] Enzymatically degradable 
hydrogels did not support ISC expansion and non-degradable 
matrices were needed. However, for organoid development 
matrix softening through ester-based hydrolysis of hybrid PEG 
gels was required.
3.4.3. Viscoelasticity
Covalently-crosslinked hydrogels are typically elastic, while 
native ECM is viscoelastic. Chaudhuri et al. observed increased 
cell spreading on soft, viscoelastic substrates compared to 
elastic gels with the same stiffness, and similar to that on 
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stiffer, elastic substrates.[102] This work was extended to 3D 
alginate-PEG based hydrogels with tunable stress relaxation, 
independent of initial stiffness, degradability and number of 
adhesion sites.[103] MSC spreading, proliferation and osteogenic 
differentiation were enhanced in rapidly relaxing hydrogels 
(τ1/2 = 70 s) compared to elastic gels (τ1/2 = 3300 s), for a stiff-
ness of 17 kPa (Figure 6b).
3.4.4. Surface Mobility
Surface mobility is another less known and poorly exploited 
dynamic material property with the potential to alter cell behav-
iour.[104,105] Surface mobility is related to the dynamic properties 
of hydrated interfacial polymer chains triggered by their inter-
actions with the surrounding. Examples include model chem-
istries and polypeptides tethered to surfaces with spacers of 
different length, as well as PEG-based systems, which modulate 
cell adhesion, spreading and long term phenotype.[105–107]
Surface mobility is sometimes mistaken with surface stiffness 
but it is actually a different physical property. Cells transduce stiff-
ness by pulling on the surface with nanoscale forces (5.5 nN µm−2), 
normally after assembling focal adhesions.[108] Surface mobility 
only involves single receptor interactions with much lower and 
fluctuating forces (picoscale). Using model systems based on 
RGD-functionalized lipid bilayers, which are highly mobile enti-
ties, it has been shown that integrin activation and early clustering 
are independent of lateral forces and that cells on these highly 
mobile surface fail to form focal adhesions.[109,110] Very recently, 
the mobility of supported lipid bilayers has been used to control 
MSC differentiation independently of ligand density.[111]
Polymers chains are mobile elements and their dynamics 
suffer a quantitative change at the glass transition tem-
perature (Tg). At temperatures below Tg, polymer chains are 
arrested and their movement is limited to the side groups of 
the chains. However, at temperatures above Tg, polymer chains 
are highly mobile within the characteristic distance of a few 
tens of nanometers. Experiments using thin polymer films 
with nanometric thicknesses demonstrated the scale of these 
movements.[112]
Using a family of poly(alkyl acrylates) with different surface 
mobility at 37 °C, it was shown that the mobility of the polymer 
surface was indeed translated into the mobility of an interfa-
cial layer of fibronectin adsorbed on their surface. Differences 
in the mobility of the adsorbed protein layer played a role in 
cell adhesion, reorganization and differentiation, through a 
mechanism that involved cell contractility.[113,114] These findings 
on 2D surfaces have recently been extended to 3D matrices. 
Novel sliding hydrogels, with stable chemical crosslinks com-
bined with mobile crosslinks and mobile biochemical ligands, 
were shown to support cellular reorganization of surrounding 
ligands, changes in cell shape and differentiation.[115]
3.5. Spatial Patterns or Gradients of Physical Cues
3.5.1. Spatial Patterns of Stiffness
Not only the magnitude, but also the spatial distribution or 
gradients of matrix physical cues can influence cell function. 
It was shown that gradients in substrate rigidity guide cell 
migration, with cells preferentially migrating from soft towards 
Adv. Healthcare Mater. 2017, 6, 1700052
Figure 6. Time-dependent biomaterial physical properties such as degradability (a) or viscoelasticity (b) can also direct osteogenic differentiation, 
for an equivalent matrix stiffness. Scale bars: (a-i) 10 µm, (a-ii) 25 µm, (a-iii) 20 µm, (b-i) 100 µm for the larger image and 20 µm for the insert, (b-ii) 
25 µm. a) Reproduced with permission.[101] Copyright 2013, Macmillan Publishers Limited. b) Reproduced with permission.[103] Copyright 2016, Macmillan 
Publishers Limited.
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stiffer substrates (durotaxis).[116] Recently, Trepat and colleagues 
observed that durotaxis can be an emergent property in a col-
lective of epithelial cells, even if isolated cells did not show this 
effect.[117] Marklein and Burdick used sequential crosslinking of 
HA hydrogel to create spatial patterns of stiffness ranging from 
3–100 kPa and observed higher MSC spreading and prolifera-
tion on stiffer regions.[118] In a following study, hepatic stellate 
cell differentiation into myofibroblasts was observed on large 
(1 mm diameter) islands with higher stiffness (23.8 ± 4.6 kPa), 
while they remained quiescent on soft substrates (2.1 ± 0.7 kPa) 
or on small (50 µm diameter), stiff islands that prevented cell 
spreading.[119] In a recent study, Yang and colleagues showed 
that the subcellular, microscale spatial distribution of matrix 
mechanical properties affect MSC function, with regular 
(random) distribution of stiff regions resulting in cell spreading 
(round morphology) and higher (lower) Yes-associated protein 
(YAP) activation.[120]
3.5.2. Spatial Patterns of Topography
Cells can also sense gradients in topography. Fibroblasts plated 
on grooves with 1 µm width and 400 nm depth oriented more 
strongly along the direction of ridges and migrated faster 
compared to sparser areas with width up to 9.1 µm.[121] Fur-
thermore, in the short term cells migrated along the pattern 
orientation, while in the long term, they migrated towards 
denser areas both in unidirectional[121] and 2D rectangular 
lattices.[122] Sochol and colleagues investigated the combined 
effect of topography of microposts with varying stiffness and 
showed that endothelial cells preferentially migrated towards 
stiffer microposts, with a migration speed proportional to the 
gradient strength.[123] Recently, Levchenko and colleagues 
described the guided migration of invasive and non-invasive 
melanoma cells according to the gradient in matrix nano-
topograpy.[124] They showed that invasive (non-invasive) cells 
migrated towards sparser (denser) areas and concluded that the 
topotactic response depends on both the density and structure 
of the ECM, and the stiffness of the cell itself.
3.5.3. Spatial Patterns of Degradability
Gradients in biomaterial degradation and resulting dynamic 
biomaterial properties, such as time-dependent topography 
or stiffness, are beginning to attract attention both in 2D and 
3D synthetic environments. Anseth and colleagues employed 
photo degradable PEG-based hydrogels – tunable in situ by UV 
light, visible light or irradiation in the presence of encapsu-
lated cells – to create channels that allowed cell spreading and 
migration in 3D or to release specific functional groups on-
demand.[125] This work was extended to click-based hydrogels 
that allow orthogonal and spatiotemporal control of photo-
cleavage of crosslinks and photoconjugation of functional 
groups.[126] Heilshorn and colleagues developed protein poly-
mers with tailored degradation rates to create dynamic struc-
tures emerging over time through enzymatic degradation in 
the bulk or on the hydrogel surface, as well as to release bio-
molecules with distinct spatiotemporal patterns.[127] In another 
study, spatial patterns of enzymatic degradation in HA hydro-
gels were used to enable or inhibit cell remodelling required for 
vascular network formation.[128]
3.6. Multiple Features of the Physics of the ECM and the Effect 
on Ligand Clustering
The improved understanding of the role of various aspects of 
the physics of the ECM on cell response has also led to some 
controversies, as to which are the key parameters modu-
lating matrix mechanosensing. Various physical cues of the 
ECM have been shown to induce osteogenic differentiation of 
MSCs in 3D: (i) the bulk stiffness of non-degradable, ionically 
crosslinked alginate hydrogels,[62] (ii) the degradability of cova-
lently crosslinked HA hydrogels, for an equivalent stiffness[101] 
and (iii) the viscoelastic properties of ionically crosslinked algi-
nate hydrogels with a polyethylene glycol spacer, for an equiv-
alent stiffness and in the absence of matrix degradation.[103] 
These studies utilize different hydrogel systems and behave 
differently at a molecular level. However, ligand clustering 
was identified as a common underlying effect in the ionically 
crosslinked alginates and degradable, covalently crosslinked HA 
hydrogels.[129] Ionically crosslinked alginates are flexible and 
cells could reorganize the surrounding RGD ligands bound to 
the matrix and thereby their focal adhesions, in the absence of 
changes in cell shape or matrix degradation. The stiffness that 
allowed maximal α5-integrin-RGD clustering correlated with 
MSC osteogenic differentiation. Covalently crosslinked HA gels 
are more stable and matrix degradation was likely required to 
reach otherwise unavailable RGD ligands and generate high 
traction forces and osteogenic differentiation. Chaudhuri and 
colleagues also observed a correlation between faster relaxing 
gels and osteogenesis, with enhanced RGD ligand clustering 
and local hydrogel remodelling.[103] Baker and colleagues 
showed that in fibrillar microenvironments, soft fibres favoured 
fibre recruitment by cells, increased local ligand density, focal 
adhesion assembly, cell spreading and proliferation.[66] Not only 
ligand density and spatial distribution, but also ligand mobility 
determines how cells sense the ECM and adapt their shape, 
motility and fate.[113–115] It seems that various aspect of the 
physical ECM could relate back to integrin clustering associated 
to local ligand density and mobility.
4. The Interplay Between Growth Factor Signalling 
and Mechanotransduction
Cells respond to the mechanical properties of the microen-
vironment. This progress report has shown examples of how 
elastic and viscoelastic properties influence cell behaviour, 
including cell adhesion, cell migration and cell differentiation. 
For example, MSCs are committed to osteoblasts on rigid sub-
strates (>25 kPa) but to adipocytes on soft ones (<10 kPa).[61] 
It is remarkable that the mechanical properties of the environ-
ment (i.e. the ECM in vivo) play a key role regardless of the bio-
chemical ‘soluble’ environment: even using osteogenic media, 
MSCs did not follow the osteogenic lineage unless the stiffness 
of the substrate was above a certain threshold.[61] This seminal 
Adv. Healthcare Mater. 2017, 6, 1700052
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work revealed how determinant the physical properties of the 
ECM are and suggested a certain preferential influence of phys-
ical over biochemical signalling. However, Picart and colleagues 
realized that the preponderance in terms of physical vs. bio-
chemical signalling was also related to the way growth factors 
were presented to cells.[130] Using a model of mouse myoblast 
C2C12 cells they showed that on stiff LbL-based surfaces cells 
respond to both solid-phase BMP-2 and soluble BMP-2 in the 
culture media. However, on softer surfaces cells did not differ-
entiate in the presence of soluble BMP-2 but indeed followed 
osteogenic commitments using solid-phase presentation of 
BMP-2, i.e. matrix bound BMP-2. These experiments demon-
strated the subtle interplay between integrins and focal adhe-
sions as mechanoreceptors that feel the substrate stiffness[131] 
and GF receptors that transduce biochemical signals. The com-
bined effect of the stiffness of the environment and BMP-2 
was also described in 3D by using gelatin based hydrogels and 
C2C12 commitment to osteogenic lineages.[132] In this study, 
authors modulated the crosslinking degree of gelatin gels and 
investigated the osteogenic differentiation with or without 
BMP-2 supplemented in the culture medium. The preferential 
role of stiffer substrates in promoting osteogenesis was shown 
with and without BMP-2 but the lack of osteogenicity in softer 
substrates was overcome in the presence of BMP-2.[132]
The importance of matrix stiffness in combination with the 
spatial distribution of GFs has been investigated using other 
cell types. Chang et al. showed that hepatocyte GF (HGF) has 
a stronger effect on endothelial cells on lower stiffness sub-
strates, in terms of cell migration and differentiation.[133] Using 
LbL-based substrates of different stiffness, they demonstrated 
that endothelial cell adhesion, migration and proliferation were 
positively correlated with increasing substrate stiffness and this 
behaviour was further promoted by HGF. Interestingly, they 
showed that the effect of HGF on cell migration and prolif-
eration was stronger on soft substrates, suggesting that HGF 
can profoundly influence the stiffness-dependent endothe-
lial cell response. In addition to this, this paper demonstrated 
that endothelial cell function (monolayer integrity, nitric oxide 
production and gene expression of endothelial nitric oxide 
synthase) displayed a negative correlation with substrate stiff-
ness. An improvement was observed with the addition of HGF 
but the effect was not strong enough to change the stiffness-
dependent endothelial cell response, i.e. functionality on stiff 
substrates in the presence of HGF was still below functionality 
on softer substrates in the absence of HGF.[133]
The interplay between stiffness and growth factor signalling 
has also been investigated in the context of MSC differentiation, 
with different results depending on the GF and immobilisation 
technique used. Zouani et al. used surfaces of different stiffness 
and a BMP-2 mimetic-peptide to identify a minimal threshold 
of stiffness (≈3.5 kPa) below which the presence of the GF had 
no effect on MSC differentiation. For stiffness values above this 
threshold, and in combination with BMP-2, cells were com-
mitted to osteogenesis.[134] Note that osteogenic commitment 
in the absence of immobilized BMP-2 was only obtained on 
stiffer surfaces (>25 kPa). In addition to the combined effect of 
mechanical properties and the presentation of GFs, Banks and 
colleagues developed a platform for independent manipulation 
of mechanical properties and spatially controlled presentation 
of BMP-2 and PDGF using collagen-GAGs with controlled 
crosslinking density. Carbodiimide crosslinking coordinated 
with benzophenone photo-immobilization allowed orthogonal 
manipulation of mechanical stiffness and immobilization of 
GFs to a collagen-GAG biomaterial. They showed that adipose 
stem cells were responsive to certain combinations of substrate 
stiffness and PDGF densities, while a lack of correlation was 
found with BMP-2, which contradicts previous findings.[135] 
This paper highlights how the bioactivity and lineage commit-
ment of adipose stem cells depend on a variety of biophysical 
and biochemical cues, whose optimal combinations are difficult 
to predict and deserve further investigation.[135]
The interplay between physical properties of the matrix and 
biochemical stimuli (including GF receptor activation and sign-
aling) has also been demonstrated using peptide amphiphiles 
(PA). PA molecules assemble into supramolecular nanofibres 
that have been engineered to incorporate sequences that bind 
GFs.[136] Stupp and colleagues designed structures that promoted 
differential raft mobility within the cell membrane and incorpo-
rated sequences to bind BMP-2 (Figure 7a). Two PAs with similar 
charge and molecular architecture were designed with different 
propensities for β-sheet hydrogen bonding. Both molecules were 
similar in amino acid composition with the exception of valine, 
which has a strong preference to adopt a β-sheet secondary struc-
ture (strong PA, Figure 7a) or glycine, which prefers a random 
coil conformation and then reduces the degree of intermolecular 
hydrogen bonding (weak PA, Figure 7a).[137] Positively charged 
lysine residues promote the association of PA nanostructures 
with the negatively charged cell surface. They showed increased 
raft mobility in samples treated with weak β-sheet PA nanofibres 
due to PA molecules intercalating within the cell membrane and 
lipid-rich microdomains. Importantly, this work showed that 
these structures that maximise cell membrane mobility (weak 
PA) also promoted more effective osteogenic differentiation and 
signalling in the presence of BMP-2 (Figure 7b). Mechanisms 
involved the electrostatic interaction between the PA and GFs 
that can localize the ligand at the cell surface in proximity to the 
signalling receptors that reside in the lipid-rich microdomains. 
Furthermore, the increased mobility of the lipid rafts after treat-
ment with PA nanofibres might increase the statistical prob-
ability of a ligand−receptor interaction. This work offers another 
very different example of the interplay between physical factors 
(i.e. membrane mobility) and the presentation of GFs from 
biomaterials.[137] In relation to this work, we have previously 
discussed that fibronectin on polymer surfaces with different 
mobility (a family of polyacrylates with increased length of the 
side chain that translated different mobility of the polymer back-
bone into mobility of fibronectin adsorbed onto it) promoted dif-
ferential cell adhesion and differentiation.[113,114] As fibronectin 
contains GF binding sites, the role of sequestered GFs from the 
surrounding media on these surfaces with different mobility 
might play an additional role on the effect of mobility in combi-
nation with integrin clustering.[37]
Mechanisms by which matrix elasticity influence GF signal-
ling are only starting to be elucidated. Ingber and colleagues 
showed that angiogenesis – a process that is controlled by 
physical interactions between cells and the ECM as well 
as GFs such as VEGF – is also controlled by a signalling 
pathway that involves the Rho inhibitor p190RhoGAP. This is 
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a mechanosensitive transcriptional factor that controls VEGF 
receptor 2 (VEGFR2) promoter activity and expression. Impor-
tantly, this novel angiogenesis signalling pathway is sensitive 
to ECM elasticity as well as VEGF (Figure 7c).[138] This work 
suggested that an appropriate level of ECM stiffness might be 
required for optimal VEGFR2 expression and vascular develop-
ment in vitro and in vivo. More recently, Picart and colleagues 
investigated mechanisms by which BMP-2 presented from sur-
faces is internalized by cells, and found this process to be also 
dependent on the stiffness of the substrate from which the GF 
was presented, with higher internalisation rates on soft sub-
strates.[30] They showed that internalization is mediated by both 
clathrin and caveolin-dependent pathways. While inhibiting 
clathrin-dependent endocytosis affected only non-canonical 
(ALP) signalling, blocking caveolin-1-dependent endocytosis 
reduced both canonical and non-canonical BMP signalling. The 
signalling pathways found for matrix-bound BMP-2 were sim-
ilar to those found for soluble BMP-2.[30]
In translational research, the complementary effect of scaf-
fold architecture and growth factor stimulation was shown in a 
30 mm critical-sized segmental bone defect in sheep tibiae.[139] 
It was shown that the scaffold geometry guides in vivo soft 
tissue formation and following mineralization.[140] The delivery 
of BMP complemented the guiding effect of the scaffold 
architecture, without altering the microstructure of the newly 
formed bone at different length scales.[139]
5. Conclusions and Outlook
Engineering material systems to control cell fate is at the 
cornerstone of a broad range of applications in regenerative 
medicine, cancer research and drug testing. There is strong 
evidence that material physical properties influence cell behav-
iour, including stem cell differentiation. Seminal papers have 
shown that stiffness, geometry, ligand spacing, time-dependent 
properties, such as matrix stiffening, degradability, viscoelas-
ticity or surface mobility, and spatial patterns or gradients of 
physical cues can trigger specific signalling pathways. On a 
parallel note, growth factors have been used mainly as soluble 
molecules to induce particular cell responses (e.g. growth or 
differentiation). However, there is increasing evidence that the 
presentation of GFs from a solid phase, recapitulating the way 
this is done in the ECM, is more efficient and can trigger cell 
response more specifically. This has been shown not only by 
engineering surfaces that promote GF binding but also, and 
importantly, by doing protein engineering and modifying GFs 
with key domains that bind the ECM.
Integrins and focal adhesions are mechanosensors, which 
transduce physical stimuli into biochemical reactions, whereas 
GF receptors initiate specific GF-related signalling cascades. 
Basic biological experiments revealed that integrin-GF receptor 
crosstalk was a way to produce synergistic signalling and, thus, 
some efforts have been put since then to engineer material sys-
tems that target simultaneously integrins and GF receptors. 
This strategy might have translational consequences, as this is 
a way to dramatically reduce the dose of GFs to produce similar 
biological effects. Therefore, it has the potential to revolutionize 
the use of GFs in the clinic, which is currently undermined by 
the side effects mainly related to the high doses applied with 
conventional delivery systems. For example, it is well known 
that BMP-2 has been widely used in clinical applications, in 
particular in spinal fusion. A collagen sponge loaded with a 
high dose of BMP-2 (1.5 mg ml−1) is effective in promoting 
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Figure 7. Combination of physical properties and growth factors. a) Peptide amphiphiles (PA) molecules assembled into supramolecular nanofibres 
that have been engineered to show either strong or weak intermolecular hydrogen bonding which promote lipid raft mobility differently. The inserts 
show wide-angle X-ray scattering from solutions of both assemblies (the arrow shows spacing for β-sheet hydrogen bonding). b) Fast blue staining to 
visualize ALP shows the differential effect of both PAs in the presence of BMP-2. Only weak PA and BMP-2 promotes osteogenesis. c) Matrix elasticity 
controls the expression of VEGFR2 in endothelial cells and then vascular development in vitro and in vivo. a,b) Reproduced with permission.[137] Copy-
right 2009, American Chemical Society. c) Reproduced with permission.[138] Copyright 2009, McMillan Publishers Limited.
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bone formation but also has involved a high number of off-
target unwanted effects, including ectopic bone formation, 
neurological problems, difficulty in breathing, and high risk 
of cancer.[141] This led the U.S. Food and Drug Administration 
(FDA) to issue a public health notification of life-threatening 
complications.[142] High dose and uncontrolled delivery of GFs 
which end up having systemic rather than local effects are 
the key issues to overcome to translate GFs into safe clinical 
applications.
In parallel, there is increasing evidence that the combination 
of physical properties (e.g. stiffness) and GF presentation also 
plays a key role in the efficiency of the system to trigger cel-
lular responses. It is especially important to further investigate 
and understand this crosstalk between physical properties (of 
carriers) and biochemical effects (of GFs) to design advanced 
systems that maximize the cellular response by using a super-
position of effects. Advances in this field have shown, e.g., 
how osteogenesis can be achieved on soft substrates as long as 
cells are simultaneously stimulated with BMP-2. But there is 
a long road ahead to design systems that make use of syner-
gies between relevant physical properties and GFs, seeking to 
reduce the dose used in clinical applications.
The future is cooperative and we envisage the development 
of advanced systems which will use GFs in very low and effi-
cient doses in combination with key (dynamic) material proper-
ties. This will allow to engineer a broad range of material-based 
systems to support fundamental (stem) cell studies, develope 
devices for tissue engineering and engineer organoids to model 
diseases and develop treatments.
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